This circumstance mainly is based on the fact that tumor samples were limited in our study collective (specifically after already having performed detailed molecular analyses on KRAS, EGFR and PTEN[10]), a persisting and well known hurdle for many international collaborative groups that conduct translational research in advanced pancreatic cancer[25]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.